Effect of intravenous magnesium sulfate on chronic obstructive pulmonary disease exacerbations requiring hospitalization: A randomized placebo-controlled trial;Efecto del sulfato de magnesio intravenoso en la exacerbación de la EPOC que precisa hospitalización: Estudio aleatorizado controlado con placebo

Archivos de Bronconeumologia

Volumn 42, Issue 8, 2006, Pages 384-387

  Abreu González, Juan ^a   Hernández García, Concepción ^a   Abreu González, Pedro ^b   Martín García, Candelaria ^a   Jiménez, Alejandro ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Bronchodilator agents; Chronic obstructive pulmonary disease, COPD; Magnesium sulfate

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; MAGNESIUM SULFATE; OXYGEN; PLACEBO; SALBUTAMOL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

EID: 33748766088     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13091646     Document Type: Article

References (23)

1. Rodríguez Roisin R, Macnee W. Pathophysiology of chronic obstructive pulmonary disease. Eur Respir J. 1998;7:107-26.
2. Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC. Arch Bronconeumol. 2004;40:315-25.
3. Calverley PMA. Patient selection for COPD therapy. Eur Respir Rev. 1999;9:179-83.
4. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD. Chest. 2000;117:42S-7S.
5. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J. 1998;12:799-804.
6. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilator in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987;135:1069-74.
7. Sharma SK, Bhargava A, Pande JN. Effect of parenteral magnesium sulfate on pulmonary functions in bronchial asthma. J Asthma. 1994;31:109-15.
8. Skobeloff EM, Spivey WH, McNamara RM, Greenspont L. Intravenous magnesium sulfate for treatment of acute asthma in the emergency department. JAMA. 1989;262:1210-3.
9. Devi PR, Kumar L, Singhi SC, Prasad R, Singh M. Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy. Indian Pediatr. 1997;34:389-97.
10. Silverman RA, Osborn H, Runge J, Gallagher EJ, Chian W, Feldman J, et al; Acute Asthma/Magnesium Study Group. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest. 2002;122:489-97.
11. Glover ML, Machado C, Totapally BR. Magnesium sulphate administered via continuous intravenous infusion in pediatric patients with refractory wheezing. Br J Crit Care. 2002;17:255-8.
12. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 1995;155:496-500.
13. Sanchís Aldás J, Casan Clarà P, Castillo Gómez J, González Mangado N, Palenciano Ballesteros L, Roca Torrent J. Espirometría forzada. En: Recomendaciones SEPAR. Barcelona: Ediciones Doyma S.A.; 1998. p. 1-18.
14. Clark NM, Evans D, Mellis RB. Patient use of peak monitoring. Am Rev Respir Dis. 1992;154:722-5.
15. Haren DL, Marion RJ, Kotses H, Creer JL. Effect of subject effort on pulmonary function measures: a preliminary investigation. J Asthma. 1984;21:295-8.
16. Cross D, Nelson HS. The role of the peak flow meter in the diagnosis and management of asthma. J Allergy Clin Immunol. 1991;87:120-8.
17. Nannini LJ, Pendino JC, Corna RA, Mannarino S, Quispe R. Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. Am J Med. 2000;108:193-7.
18. Skorodin MS, Freebeck PC, Yetter B, Nelson JE, Van de Graff WB, Walsch J. Magnesium sulfate potentiates several cardiovascular and metabolic actions of terbutaline. Chest. 1994;105:701-5.
19. Classen HG, Jacob R, Schimatschek H. Interactions of magnesium with direct and indirect-acting sympathomimetic amines. Mag Bull. 1987;9:80-7.
20. Pauwles RA, Buits AS, Calverley PM, Jenkins CR, Hurd SS, the GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHL/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
21. Barberá JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, et al. Guía clínica para el diagnóstico y tratamiento de la enfermedad pulmonar obstructiva cronica. Arch Bronconeumol. 2001;37:297-316.
22. Watson A, Lim TK, Joyce H, Pride NB. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest. 1992;101:350-5.
23. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005;60:730-4.